~~<i id='D847B2D1AE'><strike id='D847B2D1AE'><tt id='D847B2D1AE'><pre id='D847B2D1AE'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

entertainment

author：leisure time 2025-09-06 03:55:34 - browse：4346

Acadia Pharmaceuticals said Monday that its approved medicine called Nuplazid failed to improve the social and emotional symptoms of schizophrenia in a late-stage clinical trial.

The negative outcome of the Phase 3 study represents a setback in the company’s efforts to expand the use of Nuplazid into the treatment of schizophrenia. The medicine is currently approved to treat hallucinations and delusions associated with Parkinson’s disease psychosis.

“We are disappointed the trial did not meet its primary endpoint given the significant unmet need in patients with negative symptoms of schizophrenia,” said Acadia CEO Steve Davis, in a statement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： US judge blocks portions of new Florida elections law

hotspot

knowledge

explore

hotspot

FILE-Visitorslookatthe5,000year-oldremainsofSkaraBraevillageintheScottishOrkneyIslands,July19,2005,w

WSS

Pfizer, Moderna say biotech, pharma drug development is a sprint

Noem? Reynolds? A very early look at the Republican 'veepstakes'

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Leon Gautier, last member of French D

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Leon Gautier, last member of French D

leisure time

entertainment

hotspot

Bright Health sells Medicare Advantage business to Molina

This gene therapy has record $4.25 million price. It's saved children.

At least 13 dead in Texas as scorching temps continue

Texas board proposes rules on abortion law emergency exemption

Drug repurposing or repositioning? The language matters

EU climate chief is concerned over the expansion of the coal industry in China

Apple is now the first public company to be valued at $3 trillion

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Medical leaders decry Supreme Court decision on affirmative action

Chicago flooding is stark reminder of vulnerability of major cities during extreme weather

hotspot

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Kremlin open to talks over potential prisoner swap involving detained US reporter Evan Gershkovich

Pfizer, Moderna say biotech, pharma drug development is a sprint

Greece's new parliament sworn in following conservative party's election victory

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

CRISPR technology availability, affordability needs to be expanded

hotspot

knowledge

explore

hotspot